T he treatment of dyslipidemia with statin therapy is a cornerstone in the management of patients in both the primary and secondary prevention settings. Dyslipidemia is widely prevalent in its various forms (1). The lowering of low-density lipoprotein cholesterol (LDL-C) with a statin in patients with established coronary heart disease (CHD) has shown unequivocal capacity to safely reduce risk for clinical sequelae such as nonfatal myocardial infarction, ischemic stroke, cardiovascular and all-cause mortality, as well as the need for revascularization (2,3). The American College of Cardiology/American Heart Association Guideline for the Treatment of Blood Cholesterol continues to place primary emphasis on cardiovascular (CV) risk reduction by lowering LDL-C by a specific percentage according to estimated level of risk for sustaining an acute CV event (4). Statin therapy generally lowers risk for an acute CV event by 25% to 45% over 5 years of follow-up, depending upon the magnitude of LDL-C reduction, specific patient characteristics, and the intensity of statin therapy used. Consistent with these findings, the "residual risk" for a CV event is estimated as being 55% to 75%. Clearly, not all of the residual risk is attributable to dyslipidemia. Persistent cigarette smoking, inadequately controlled hypertension, obesity, insulin resistance, and other risk factors all contribute. However, because elevated triglycerides and non-high-density lipoprotein cholesterol (HDL-C) and low HDL-C have also been shown to be independent risk factors for CV events, there has been understandable motivation to address this residual risk with use of adjuvant lipid-modifying therapies that provide incremental LDL-C lowering, triglycerides and non-HDL-C reduction, and HDL-C elevation. The treatment of elderly patients ($65 years of age)
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The treatment of elderly patients ($65 years of age)
is an issue that is often met with some trepidation. Vytorin Efficacy International Trial), we now have evidence that the addition of ezetimibe to statin therapy is safe and provides a degree of risk reduction that is commensurate with the magnitude of LDL-C reduction in patients who have sustained an acute coronary syndrome (17) . Understandably, it is anticipated that the use of ezetimibe will gradually increase in response to these findings. A very interesting finding is that, despite having evidence for reducing cardiovascular events (18) , bile acid binding resin therapy did not increase as ezetimibe use decreased.
In contrast to prescribing patterns with ezetimibe, publication of the negative ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial had little to no effect on the prescribing of fenofibrate (19 There is much yet to be learned about residual risk and the role of adjuvant lipid-lowering therapy.
However, as this study makes clear, the prescribing of lipid-lowering medication by health care providers and its responsiveness to clinical trials is an issue that warrants much careful additional study. In the meantime, it is crucial that statins and adjuvant therapies with demonstrable efficacy be used appropriately to help more patients achieve guideline-determined goals for LDL-C reduction, especially among elderly patients.
